246 related articles for article (PubMed ID: 30460349)
21. Modulation of CD47-SIRPα innate immune checkpoint axis with Fc-function detuned anti-CD47 therapeutic antibody.
Narla RK; Modi H; Bauer D; Abbasian M; Leisten J; Piccotti JR; Kopytek S; Eckelman BP; Deveraux Q; Timmer J; Zhu D; Wong L; Escoubet L; Raymon HK; Hariharan K
Cancer Immunol Immunother; 2022 Feb; 71(2):473-489. PubMed ID: 34247273
[TBL] [Abstract][Full Text] [Related]
22. CD47-SIRPα Interactions Regulate Macrophage Uptake of Plasmodium falciparum-Infected Erythrocytes and Clearance of Malaria In Vivo.
Ayi K; Lu Z; Serghides L; Ho JM; Finney C; Wang JCY; Liles WC; Kain KC
Infect Immun; 2016 Jul; 84(7):2002-2011. PubMed ID: 27091932
[TBL] [Abstract][Full Text] [Related]
23. CD47-SIRPα Checkpoint Disruption in Metastases Requires Tumor-Targeting Antibody for Molecular and Engineered Macrophage Therapies.
Andrechak JC; Dooling LJ; Tobin MP; Zhang W; Hayes BH; Lee JY; Jin X; Irianto J; Discher DE
Cancers (Basel); 2022 Apr; 14(8):. PubMed ID: 35454837
[TBL] [Abstract][Full Text] [Related]
24. Targeting Fc Receptor-Mediated Effects and the "Don't Eat Me" Signal with an Oncolytic Virus Expressing an Anti-CD47 Antibody to Treat Metastatic Ovarian Cancer.
Tian L; Xu B; Teng KY; Song M; Zhu Z; Chen Y; Wang J; Zhang J; Feng M; Kaur B; Rodriguez L; Caligiuri MA; Yu J
Clin Cancer Res; 2022 Jan; 28(1):201-214. PubMed ID: 34645647
[TBL] [Abstract][Full Text] [Related]
25. Gentulizumab, a novel anti-CD47 antibody with potent antitumor activity and demonstrates a favorable safety profile.
Wang T; Wang SQ; Du YX; Sun DD; Liu C; Liu S; Sun YY; Wang HL; Zhang CS; Liu HL; Jin L; Chen XP
J Transl Med; 2024 Mar; 22(1):220. PubMed ID: 38429732
[TBL] [Abstract][Full Text] [Related]
26. CD47-signal regulatory protein α signaling system and its application to cancer immunotherapy.
Murata Y; Saito Y; Kotani T; Matozaki T
Cancer Sci; 2018 Aug; 109(8):2349-2357. PubMed ID: 29873856
[TBL] [Abstract][Full Text] [Related]
27. The CD47-SIRPα axis is a promising target for cancer immunotherapies.
Hao Y; Zhou X; Li Y; Li B; Cheng L
Int Immunopharmacol; 2023 Jul; 120():110255. PubMed ID: 37187126
[TBL] [Abstract][Full Text] [Related]
28. Delivery of CD47 blocker SIRPα-Fc by CAR-T cells enhances antitumor efficacy.
Chen H; Yang Y; Deng Y; Wei F; Zhao Q; Liu Y; Liu Z; Yu B; Huang Z
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35110357
[TBL] [Abstract][Full Text] [Related]
29. Attenuation of CD47-SIRPα Signal in Cholangiocarcinoma Potentiates Tumor-Associated Macrophage-Mediated Phagocytosis and Suppresses Intrahepatic Metastasis.
Vaeteewoottacharn K; Kariya R; Pothipan P; Fujikawa S; Pairojkul C; Waraasawapati S; Kuwahara K; Wongkham C; Wongkham S; Okada S
Transl Oncol; 2019 Feb; 12(2):217-225. PubMed ID: 30415063
[TBL] [Abstract][Full Text] [Related]
30. SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells.
Tahk S; Vick B; Hiller B; Schmitt S; Marcinek A; Perini ED; Leutbecher A; Augsberger C; Reischer A; Tast B; Humpe A; Jeremias I; Subklewe M; Fenn NC; Hopfner KP
J Hematol Oncol; 2021 Sep; 14(1):155. PubMed ID: 34579739
[TBL] [Abstract][Full Text] [Related]
31. Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPα.
Sim J; Sockolosky JT; Sangalang E; Izquierdo S; Pedersen D; Harriman W; Wibowo AS; Carter J; Madan A; Doyle L; Harrabi O; Kauder SE; Chen A; Kuo TC; Wan H; Pons J
MAbs; 2019; 11(6):1036-1052. PubMed ID: 31257988
[TBL] [Abstract][Full Text] [Related]
32. BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells.
van Helden MJ; Zwarthoff SA; Arends RJ; Reinieren-Beeren IMJ; Paradé MCBC; Driessen-Engels L; de Laat-Arts K; Damming D; Santegoeds-Lenssen EWH; van Kuppeveld DWJ; Lodewijks I; Olsman H; Matlung HL; Franke K; Mattaar-Hepp E; Stokman MEM; de Wit B; Glaudemans DHRF; van Wijk DEJW; Joosten-Stoffels L; Schouten J; Boersema PJ; van der Vleuten M; Sanderink JWH; Kappers WA; van den Dobbelsteen D; Timmers M; Ubink R; Rouwendal GJA; Verheijden G; van der Lee MMC; Dokter WHA; van den Berg TK
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37068796
[TBL] [Abstract][Full Text] [Related]
33. Myelin down-regulates myelin phagocytosis by microglia and macrophages through interactions between CD47 on myelin and SIRPα (signal regulatory protein-α) on phagocytes.
Gitik M; Liraz-Zaltsman S; Oldenborg PA; Reichert F; Rotshenker S
J Neuroinflammation; 2011 Mar; 8():24. PubMed ID: 21401967
[TBL] [Abstract][Full Text] [Related]
34. Attenuation of phagocytosis of xenogeneic cells by manipulating CD47.
Wang H; VerHalen J; Madariaga ML; Xiang S; Wang S; Lan P; Oldenborg PA; Sykes M; Yang YG
Blood; 2007 Jan; 109(2):836-42. PubMed ID: 17008545
[TBL] [Abstract][Full Text] [Related]
35. CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy.
Wang H; Sun Y; Zhou X; Chen C; Jiao L; Li W; Gou S; Li Y; Du J; Chen G; Zhai W; Wu Y; Qi Y; Gao Y
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020240
[TBL] [Abstract][Full Text] [Related]
36. Development of AO-176, a Next-Generation Humanized Anti-CD47 Antibody with Novel Anticancer Properties and Negligible Red Blood Cell Binding.
Puro RJ; Bouchlaka MN; Hiebsch RR; Capoccia BJ; Donio MJ; Manning PT; Frazier WA; Karr RW; Pereira DS
Mol Cancer Ther; 2020 Mar; 19(3):835-846. PubMed ID: 31879362
[TBL] [Abstract][Full Text] [Related]
37. Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation.
Marquardt V; Theruvath J; Pauck D; Picard D; Qin N; Blümel L; Maue M; Bartl J; Ahmadov U; Langini M; Meyer FD; Cole A; Cruz-Cruz J; Graef CM; Wölfl M; Milde T; Witt O; Erdreich-Epstein A; Leprivier G; Kahlert U; Stefanski A; Stühler K; Keir ST; Bigner DD; Hauer J; Beez T; Knobbe-Thomsen CB; Fischer U; Felsberg J; Hansen FK; Vibhakar R; Venkatraman S; Cheshier SH; Reifenberger G; Borkhardt A; Kurz T; Remke M; Mitra S
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36639156
[TBL] [Abstract][Full Text] [Related]
38. Macrophages show higher levels of engulfment after disruption of
Hayes BH; Tsai RK; Dooling LJ; Kadu S; Lee JY; Pantano D; Rodriguez PL; Subramanian S; Shin JW; Discher DE
J Cell Sci; 2020 Mar; 133(5):. PubMed ID: 31964705
[TBL] [Abstract][Full Text] [Related]
39. Selective SIRPα blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance.
Gauttier V; Pengam S; Durand J; Biteau K; Mary C; Morello A; Néel M; Porto G; Teppaz G; Thepenier V; Danger R; Vince N; Wilhelm E; Girault I; Abes R; Ruiz C; Trilleaud C; Ralph K; Trombetta ES; Garcia A; Vignard V; Martinet B; Glémain A; Bruneau S; Haspot F; Dehmani S; Duplouye P; Miyasaka M; Labarrière N; Laplaud D; Le Bas-Bernardet S; Blanquart C; Catros V; Gouraud PA; Archambeaud I; Aublé H; Metairie S; Mosnier JF; Costantini D; Blancho G; Conchon S; Vanhove B; Poirier N
J Clin Invest; 2020 Nov; 130(11):6109-6123. PubMed ID: 33074246
[TBL] [Abstract][Full Text] [Related]
40. SIRPα-Antibody Fusion Proteins Selectively Bind and Eliminate Dual Antigen-Expressing Tumor Cells.
Piccione EC; Juarez S; Tseng S; Liu J; Stafford M; Narayanan C; Wang L; Weiskopf K; Majeti R
Clin Cancer Res; 2016 Oct; 22(20):5109-5119. PubMed ID: 27126995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
